The global market for the prostate cancer therapeutics market is increasing, driven primarily by the growth in the hormone-refractory prostate cancer therapeutics market.
Global Prostate Cancer Drugs Analysis: Zytiga was the leading prostate cancer drugs in 2014 being followed by Xtandi drugs.
During the study, which tracked the men for nearly a decade, prostate cancer
was diagnosed in 21 daytime workers, 3 nighttime workers, and 7 shift workers.
This study will provide data on the ability of OGX-011 to enhance the activity of hormone ablation therapy in prostate cancer
is the second leading cause of cancer death in American men (Crawford 2003).
This year, taxpayers in California and New York can contribute to the Prostate Cancer
The odds of surviving prostate cancer
for five years are 98 percent, up from 67 percent in the mid-1970s.
New research shows that men with the highest blood levels of vitamin E were five times less likely to develop prostate cancer
PSMA is a protein abundantly expressed on the surface of prostate cancer
cells, with an increased expression in high-grade cancers, metastatic disease and hormone-refractory prostate cancer
Annualized US prostate cancer
therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.
The study demonstrated that if a PCA3 DD3 test were negative for prostate cancer
, there would be a 90% chance that a subsequent biopsy would be negative.
Alavanja, a senior investigator with the National Cancer Institute, analyzed the relationship between exposure to common agricultural pesticides and eventual development of prostate cancer
in 55,332 initially healthy men who applied pesticides in Iowa and North Carolina.
diagnosis changed dramatically with the discovery in 1979 of a protein known as prostate-specific antigen (PSA) and the introduction in the late 1980s of a test that measures its concentration in the blood.
So scaling mountains seemed like an appropriate way to honor Hap, who died of prostate cancer
One out of six American men will be diagnosed with prostate cancer
over the course his lifetime.